TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01503489

Intervention type: DRUG
Intervention: Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.
Description: Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
Study: NCT02795286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Haemodialysis Machine w/ ASIST Software - Isonatremic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Haemodialysis Machine w/ ASIST Software - Isotonic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artis Haemodialysis Machine w/o ASIST Software
Study: NCT00451620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide
Description: Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucoNorm
Description: Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
Study: NCT04083456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Biobehavioral Intervention
Description: Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
Study: NCT01105247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg daily or 840 mg daily
Study: NCT03063541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 100 mg daily as one tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive blood pressure control
Description: Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
Study: NCT02894203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Study: NCT02104089

Intervention type: DEVICE
Intervention: Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
Study: NCT03756220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy of vitamin C and thiamine
Description: Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
Study: NCT03377335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.
Study: NCT01991834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gynecologic laparoscopy
Description: Gynecological laparoscopy without opening hollow viscera.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: gynecologic laparoscopy
Description: Gynecological laparoscopy without opening hollow viscera.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous administration of 1 g of cefazolin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of saline sterile solution
Study: NCT00647855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets 300 μg
Description: 2x300mcg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid® Tablets 300 μg
Description: 2x300mcg, single dose fasting
Study: NCT02637934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging sessions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging sessions
Study: NCT03842787

Intervention type: OTHER
Intervention: Biological analysis
Description: Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy
Study: NCT04162847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud Health Intervention
Description: SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
Study: NCT01142258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive or inert pill which will be used as a comparator
Study: NCT01915277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT03586895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Connect
Description: e-Connect
Study: NCT00103792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
Study: NCT01201122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening).
Study: NCT04185025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceramides
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.
Study: NCT04145791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice
Description: ice packs
Study: NCT03477890

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).
Study: NCT03296696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 596
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 596
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Drug
Study: NCT02700230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given intratumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02409615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis Therapy
Description: A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healing Touch Therapy
Description: Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
Study: NCT04688554

Intervention type: BEHAVIORAL
Intervention: Disease-Specific Patient-Reported Outcomes
Description: Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)

Intervention type: BEHAVIORAL
Intervention: Disease-Specific Patient-Reported Outcomes
Description: Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
Study: NCT00825669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser ablation
Description: Laser ablation is given to the PVTT.
Study: NCT02989467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one placebo tablet daily for 5 consecutive days.
Study: NCT01190202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of body temperature
Description: Assessment of axial body temperature with a digital thermometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of body temperature
Description: Assessment of axial body temperature with a digital thermometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of body temperature
Description: Assessment of axial body temperature with a digital thermometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of body temperature
Description: Assessment of axial body temperature with a digital thermometer
Study: NCT00871806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial tablet with water
Description: 40 mg tablet, given once to each subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #1 without water
Description: 40 mg tablet given once to each subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #2 without water
Description: 40 mg tablet given once to each subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #1 with water
Description: 40 mg tablet given once to each subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #2 with water
Description: 40 mg tablet given once to each subject
Study: NCT00171899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT05246150

Intervention type: BEHAVIORAL
Intervention: nursing care practices
Description: To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
Study: NCT03151707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide riboside 2g/day for a 2 week duration
Study: NCT03311386

Intervention type: DRUG
Intervention: Actilyse
Description: thrombolytic therapy
Study: NCT02696304

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissu repartition
Description: absorptiometry,

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissu repartition
Description: absorptiometry,

Intervention type: OTHER
Group type: OTHER
Intervention: Visceral and liver adipose tissue repartition
Description: MRI,spectroscopy,

Intervention type: OTHER
Group type: OTHER
Intervention: Visceral and liver adipose tissue repartition
Description: MRI,spectroscopy,

Intervention type: OTHER
Group type: OTHER
Intervention: Preadipocyte quantification and adipose tissue inflamation
Description: biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Preadipocyte quantification and adipose tissue inflamation
Description: biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Inflamation blood markers quantification
Description: blood drawn,

Intervention type: OTHER
Group type: OTHER
Intervention: Inflamation blood markers quantification
Description: blood drawn,